Effect of haptoglobin on the treatment of chronic hepatitis B with interferon

Lv,Lin‑Ling; Yang,Yi‑Xuan; Shi,Tong‑Dong

doi:10.3892/etm.2019.7661

Effect of haptoglobin on the treatment of chronic hepatitis B with interferon

Authors:
- Lin‑Ling Lv
- Yi‑Xuan Yang
- Tong‑Dong Shi
View Affiliations

Affiliations: Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Chongqing Medical University, Chongqing 400016, P.R. China, Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400016, P.R. China, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: June 11, 2019 https://doi.org/10.3892/etm.2019.7661
Pages: 1417-1425

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There are two main types of drugs that are used to treat chronic hepatitis B (CHB), including interferon (IFN) and nucleotide analogues. IFN inhibits the virus through direct antiviral activity and via immune regulation, and it has been widely applied for the treatment of CHB and other infections. However, the efficiency of IFN therapy is not entirely satisfactory. The aim of the present study was to investigate the factors affecting IFN therapy. The plasma of patients with CHB treated with IFN was collected and divided into the virological response group and non‑virological response group according to their virological response. Serum proteins of virologically responsive patients were compared before and after IFN therapy using isobaric tags for relative and absolute quantitation technology. ELISA was used to validate these results in the same sample. In in vitro cell experiments, HepG2.2.15 cells were transfected with haptoglobin (Hp)‑targeting small interfering RNA to inhibit expression of the Hp protein, and reverse transcription‑quantitative polymerase chain reaction and western blotting were utilized to detect hepatitis B virus (HBV)‑DNA, IFN and downstream molecular changes in the cell supernatants. The Hp protein levels were demonstrated to be significantly lower following 48 weeks of IFN therapy, and the levels of Hp in patients in the virological response group were significantly lower than those in the non‑virological response group. In in vitro cell experiments, following inhibition of Hp protein expression, significantly decreased levels of HBV‑DNA, and elevated levels of IFN and its downstream molecules were observed. These findings suggest that Hp may be able to predict the efficacy of IFN therapy, and it may inhibit HBV clearance. There is an association between Hp and IFN, which requires further clinical and laboratory studies to explore.

View Figures

View References

1	GBD 2013 Mortality and Causes of Death Collaborators: Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: A systematic analysis for the global burden of disease study 2013. Lancet. 385:117–171. 2015. View Article : Google Scholar : PubMed/NCBI
2	Torresi J and Locarnini SA: New therapeutic strategies in the treatment of hepatitis B virus infection. Expert Opin Investig Drugs. 8:289–305. 1999. View Article : Google Scholar : PubMed/NCBI
3	van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, Schalm SW and Janssen HL: Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology. 39:804–810. 2004. View Article : Google Scholar : PubMed/NCBI
4	Sung JJ, Tsoi KK, Wong VW, Li KC and Chan HL: Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 28:1067–1077. 2008. View Article : Google Scholar : PubMed/NCBI
5	Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, et al: Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 352:2682–2695. 2005. View Article : Google Scholar : PubMed/NCBI
6	Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, et al: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet. 365:123–129. 2005. View Article : Google Scholar : PubMed/NCBI
7	Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM and Murad MH; American Association for the Study of Liver Diseases, : AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 63:261–283. 2016. View Article : Google Scholar : PubMed/NCBI
8	Rai AJ, Gelfand CA, Haywood BC, Warunek DJ, Yi J, Schuchard MD, Mehigh RJ, Cockrill SL, Scott GB, Tammen H, et al: HUPO plasma proteome project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples. Proteomics. 5:3262–3277. 2005. View Article : Google Scholar : PubMed/NCBI
9	Zhang H, Li H, Yang Y, Li S, Ren H, Zhang D and Hu H: Differential regulation of host genes including hepatic fatty acid synthase in HBV-transgenic mice. J Proteome Res. 12:2967–2979. 2013. View Article : Google Scholar : PubMed/NCBI
10	Yang Y, Toy W, Choong LY, Hou P, Ashktorab H, Smoot DT, Yeoh KG and Lim YP: Discovery of SLC3A2 cell membrane protein as a potential gastric cancer biomarker: Implications in molecular imaging. J Proteome Res. 11:5736–5747. 2012. View Article : Google Scholar : PubMed/NCBI
11	Kersey PJ, Duarte J, Williams A, Karavidopoulou Y, Birney E and Apweiler R: The international protein index: An integrated database for proteomics experiments. Proteomics. 4:1985–1988. 2004. View Article : Google Scholar : PubMed/NCBI
12	Sells MA, Chen ML and Acs G: Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA. 84:1005–1009. 1987. View Article : Google Scholar : PubMed/NCBI
13	Lepiller Q, Abbas W, Kumar A, Tripathy MK and Herbein G: HCMV activates the IL-6-JAK-STAT3 axis in HepG2 cells and primary human hepatocytes. PLoS One. 8:e595912013. View Article : Google Scholar : PubMed/NCBI
14	She S, Xiang Y, Yang M, Ding X, Liu X, Ma L, Liu Q, Liu B, Lu Z, Li S, et al: C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma. Int J Oncol. 47:543–554. 2015. View Article : Google Scholar : PubMed/NCBI
15	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
16	Zhou C, Simpson KL, Lancashire LJ, Walker MJ, Dawson MJ, Unwin RD, Rembielak A, Price P, West C, Dive C and Whetton AD: Statistical considerations of optimal study design for human plasma proteomics and biomarker discovery. J Proteome Res. 11:2103–2113. 2012. View Article : Google Scholar : PubMed/NCBI
17	Chong PK, Lee H, Zhou J, Liu SC, Loh MC, So JB, Lim KH, Yeoh KG and Lim YP: Reduced plasma APOA1 level is associated with gastric tumor growth in MKN45 mouse xenograft model. J Proteomics. 73:1632–1640. 2010. View Article : Google Scholar : PubMed/NCBI
18	Osiowy C, Coffin C and Andonov A: Review of laboratory tests used in monitoring hepatitis B response to pegylated interferon and nucleos(t)ide analog therapy. Curr Treat Options Infect Dis. 8:177–193. 2016. View Article : Google Scholar : PubMed/NCBI
19	Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW and Janssen HL: Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 137:2002–2009. 2009. View Article : Google Scholar : PubMed/NCBI
20	Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH and Aebersold R: Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol. 17:994–999. 1999. View Article : Google Scholar : PubMed/NCBI
21	Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, et al: Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics. 3:1154–1169. 2004. View Article : Google Scholar : PubMed/NCBI
22	Javid J: Human haptoglobins. Curr Top Hematol. 1:151–192. 1978.PubMed/NCBI
23	Andersen CBF, Stødkilde K, Sæderup KL, Kuhlee A, Raunser S, Graversen JH and Moestrup SK: Haptoglobin. Antioxid Redox Signal. 26:814–831. 2017. View Article : Google Scholar : PubMed/NCBI
24	Smithies O: Zone electrophoresis in starch gels: Group variations in the serum proteins of normal human adults. Biochem J. 61:629–641. 1955. View Article : Google Scholar : PubMed/NCBI
25	Lim SK: Consequences of haemolysis without haptoglobin. Redox Rep. 6:375–378. 2001. View Article : Google Scholar : PubMed/NCBI
26	Sadrzadeh SM and Bozorgmehr J: Haptoglobin phenotypes in health and disorders. Am J Clin Pathol. 121 (Suppl):S97–S104. 2004.PubMed/NCBI
27	Wang F, Huang W and Li A: Serum haptoglobin suppresses T-lymphocyte functions following burns. Chin Med Sci J. 11:180–183. 1996.PubMed/NCBI
28	Peta V, Tse C, Perazzo H, Munteanu M, Ngo Y, Ngo A, Ramanujam N, Verglas L, Mallet M, Ratziu V, et al: Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. PLoS One. 12:e01894362017. View Article : Google Scholar : PubMed/NCBI
29	Louagie H, Delanghe J, Desombere I, De Buyzere M, Hauser P and Leroux-Roels G: Haptoglobin polymorphism and the immune response after hepatitis B vaccination. Vaccine. 11:1188–1190. 1993. View Article : Google Scholar : PubMed/NCBI
30	Arredouani M, Matthijs P, Van Hoeyveld E, Kasran A, Baumann H, Ceuppens JL and Stevens E: Haptoglobin directly affects T cells and suppresses T helper cell type 2 cytokine release. Immunology. 108:144–151. 2003. View Article : Google Scholar : PubMed/NCBI
31	El Ghmati SM, Van Hoeyveld EM, Van Strijp JG, Ceuppens JL and Stevens EA: Identification of haptoglobin as an alternative ligand for CD11b/CD18. J Immunol. 156:2542–2552. 1996.PubMed/NCBI
32	Goldstein JI, Goldstein KA, Wardwell K, Fahrner SL, Goonan KE, Cheney MD, Yeager MP and Guyre PM: Increase in plasma and surface CD163 levels in patients undergoing coronary artery bypass graft surgery. Atherosclerosis. 170:325–332. 2003. View Article : Google Scholar : PubMed/NCBI
33	Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK and Moestrup SK: Identification of the haemoglobin scavenger receptor. Nature. 409:198–201. 2001. View Article : Google Scholar : PubMed/NCBI